Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.
Also called NCT05050500
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 143 participants
- Sponsor
- Registry
-
NCT05050500
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05050500. Randomized; triple masking; primary purpose treatment. Start 2023-05-08 (actual); primary completion 2024-12-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
- Condition
- Myocardial Infarction
- Condition
- Diabete Type 2
- Condition
- Glucose Intolerance
- Intervention (Drug)
- Dapagliflozin 10mg/Tab
- Intervention (Drug)
- control group
- Lead sponsor
- Qingdao Central Hospital
Record details
- Record id
cardio:ct-nct05050500- Content hash
2c25b96d2bba27241c34360c93246761bb14c1bee2abdc62c04351152b6e15fd